<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0123-3122</journal-id>
<journal-title><![CDATA[Persona y Bioética]]></journal-title>
<abbrev-journal-title><![CDATA[pers.bioét.]]></abbrev-journal-title>
<issn>0123-3122</issn>
<publisher>
<publisher-name><![CDATA[Universidad de la Sabana]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0123-31222020000200188</article-id>
<article-id pub-id-type="doi">10.5294/pebi.2020.24.2.6</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Investigación clínica y buenas prácticas clínicas. Más historias por contar]]></article-title>
<article-title xml:lang=""><![CDATA[Clinical Research and Good Clinical Practice. More Stories to Tell]]></article-title>
<article-title xml:lang=""><![CDATA[Pesquisa clínica e boas práticas clínicas. Mais histórias por contar]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Suárez Obando]]></surname>
<given-names><![CDATA[Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Pontificia Universidad Javeriana  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2020</year>
</pub-date>
<volume>24</volume>
<numero>2</numero>
<fpage>188</fpage>
<lpage>204</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0123-31222020000200188&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0123-31222020000200188&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0123-31222020000200188&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen Con el objetivo de garantizar la conducción ética de la investigación científica en seres humanos y que en su ejecución prevalezcan el interés por la salud y el bienestar de los sujetos participantes, se han desarrollado diversas pautas, normas y parámetros dirigidos a la comunidad científica que implementa la investigación en estos sujetos. Uno de esos parámetros normativos es el de las buenas prácticas clínicas, el cual, luego de su implementación a través de la Resolución 2378 de 2008, se ha convertido en un documento orientador de gran relevancia para la investigación clínica en Colombia. El presente artículo relata sus orígenes y versiones, y reflexiona sobre sus limitaciones frente al debate ético que gira alrededor de la evaluación de protocolos de investigación por parte de los comités de ética.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract For guaranteeing the ethical conduct of scientific research on human beings in which the interest in the health and well-being of the participating subjects prevail, various guidelines, standards, and parameters have been established for the scientific community. One of these regulatory parameters is good clinical practice, which, after its implementation by Resolution 2378 of 2008, has become a highly relevant guide for clinical trials in Colombia. This article relates its origins and versions and goes over its limitations regarding the ethical debate on ethics committees evaluating research protocols.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo Com o objetivo de garantir a condução ética da pesquisa científica em seres humanos e que em sua execução prevaleça o interesse pela saúde e pelo bem-estar dos sujeitos participantes, foram desenvolvidas diversas pautas, normas e parâmetros dirigidos à comunidade científica que implementa a pesquisa nesses sujeitos. Um desses parâmetros normativos é o das boas práticas clínicas, o qual, depois de sua implementação por meio da Resolução 2378 de 2008, tornou-se um documento orientador de grande relevância para a pesquisa clínica na Colômbia. O presente artigo relata suas origens e versões, e reflete sobre suas limitações com relação ao debate ético que gira em torno da avaliação de protocolos de pesquisa, por parte dos comitês de ética.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[investigación]]></kwd>
<kwd lng="es"><![CDATA[ética en investigación]]></kwd>
<kwd lng="es"><![CDATA[comités de ética]]></kwd>
<kwd lng="en"><![CDATA[Research]]></kwd>
<kwd lng="en"><![CDATA[ethics research]]></kwd>
<kwd lng="en"><![CDATA[ethics committees]]></kwd>
<kwd lng="pt"><![CDATA[Pesquisa]]></kwd>
<kwd lng="pt"><![CDATA[pesquisa em ética]]></kwd>
<kwd lng="pt"><![CDATA[comissão de ética]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[WO.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Institutional review board (IRB) and ethical issues in clinical research.]]></article-title>
<source><![CDATA[Korean J Anesthesiol.]]></source>
<year>2012</year>
<volume>62</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-12</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tannert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Elvers]]></surname>
<given-names><![CDATA[HD]]></given-names>
</name>
<name>
<surname><![CDATA[Jandrig]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The ethics of uncertainty. In the light of possible dangers, research becomes a moral duty.]]></article-title>
<source><![CDATA[EMBO Rep.]]></source>
<year>2007</year>
<volume>8</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>892-6</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suárez-Obando]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Consentimiento informado como criterio de inclusión. ¿Confusión conceptual, manipulación, discriminación o coerción?]]></article-title>
<source><![CDATA[Pers y Bioét.]]></source>
<year>2016</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>244-56</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schatz]]></surname>
<given-names><![CDATA[GS.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Are the rationale and regulatory system for protecting human subjects of biomedical and behavioral research obsolete and unworkable, or ethically important but inconvenient and inadequately enforced?]]></article-title>
<source><![CDATA[J Contemp Health Law Policy.]]></source>
<year>2003</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-31</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharp]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Brinich]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Boyle]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Coors]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Research ethics consultation: ethical and professional practice challenges and recommendations.]]></article-title>
<source><![CDATA[Acad Med.]]></source>
<year>2015</year>
<volume>90</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>615-20</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jr.]]></surname>
<given-names><![CDATA[Dixon JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The international conference on harmonization good clinical practice guideline]]></article-title>
<source><![CDATA[Qual Assur.]]></source>
<year>1998</year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>65-74</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palacios]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Las buenas prácticas clínicas en Colombia]]></article-title>
<source><![CDATA[Colombia Medica]]></source>
<year>2009</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>312-3</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vray]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Bompart]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Participants in Round Table N masculine GX. Guidelines for clinical research in developing countries.]]></article-title>
<source><![CDATA[Therapie]]></source>
<year>2007</year>
<volume>62</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>223-7</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crofton]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The MRC randomized trial of streptomycin and its legacy: A view from the clinical front line.]]></article-title>
<source><![CDATA[J R Soc Med.]]></source>
<year>2006</year>
<volume>99</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>531-4</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[AB.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chemotherapy of pulmonary tuberculosis in young adults; an analysis of the combined results of three Medical Research Council trials.]]></article-title>
<source><![CDATA[Br Med J.]]></source>
<year>1952</year>
<volume>1</volume>
<numero>4769</numero>
<issue>4769</issue>
<page-range>1162-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grabowsky]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The evolution of the pharmaceutical industry over the past 50 years: A personal reflection.]]></article-title>
<source><![CDATA[Int J of Economic Bussines.]]></source>
<year>2011</year>
<volume>18</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>161-76</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wax]]></surname>
<given-names><![CDATA[PM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act.]]></article-title>
<source><![CDATA[Ann Intern Med.]]></source>
<year>1995</year>
<volume>122</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>456-61</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borchers]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Hagie]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Keen]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Gershwin]]></surname>
<given-names><![CDATA[ME.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The history and contemporary challenges of the US Food and Drug Administration.]]></article-title>
<source><![CDATA[Clin Ther.]]></source>
<year>2007</year>
<volume>29</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[JR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 50th anniversary of the Kefauver-Harris Amendments: Efficacy assessment and the randomized clinical trial.]]></article-title>
<source><![CDATA[J Clin Hypertens (Greenwich)]]></source>
<year>2012</year>
<volume>14</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>810-5</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Scialli]]></surname>
<given-names><![CDATA[AR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thalidomide: The tragedy of birth defects and the effective treatment of disease.]]></article-title>
<source><![CDATA[Toxicol Sci.]]></source>
<year>2011</year>
<volume>122</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lachmann]]></surname>
<given-names><![CDATA[PJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals]]></article-title>
<source><![CDATA[QJM]]></source>
<year>2012</year>
<volume>105</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1179-89</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ridings]]></surname>
<given-names><![CDATA[JE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The thalidomide disaster, lessons from the past.]]></article-title>
<source><![CDATA[Methods Mol Biol]]></source>
<year>2013</year>
<numero>947</numero>
<issue>947</issue>
<page-range>575-86</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Podolsky]]></surname>
<given-names><![CDATA[SH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reform, regulation, and pharmaceuticals--the Kefauver-Harris Amendments at 50.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>2012</year>
<volume>367</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1481-3</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baron]]></surname>
<given-names><![CDATA[JH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolution of clinical research: a history before and beyond James Lind.]]></article-title>
<source><![CDATA[Perspect Clin Res.]]></source>
<year>2012</year>
<volume>3</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>149</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hellmann]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Verdi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jr.]]></surname>
<given-names><![CDATA[Schlemper BR]]></given-names>
</name>
<name>
<surname><![CDATA[Caponi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[50th anniversary of the Declaration of Helsinki: the double standard was introduced]]></article-title>
<source><![CDATA[Arch Med Res.]]></source>
<year>2014</year>
<volume>45</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>600-1</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<collab>Department of Health E, Welfare, National Commission for the Protection of Human Subjects of B, Behavioral R.</collab>
<article-title xml:lang=""><![CDATA[The Belmont Report. Ethical principles and guidelines for the protection of human subjects of research.]]></article-title>
<source><![CDATA[J Am Coll Dent.]]></source>
<year>2014</year>
<volume>81</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>4-13</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beecher]]></surname>
<given-names><![CDATA[HK.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ethics and clinical research.]]></article-title>
<source><![CDATA[N Engl J Med.]]></source>
<year>1966</year>
<volume>274</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>1354-60</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[ten Have]]></surname>
<given-names><![CDATA[HA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Potter&#8217;s notion of bioethics]]></article-title>
<source><![CDATA[Kennedy Inst Ethics J.]]></source>
<year>2012</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>59-82</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Masuyama]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Isobe]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Social change and Pharmaceutical Affairs Law (PAL).]]></article-title>
<source><![CDATA[Yakushigaku Zasshi]]></source>
<year>2010</year>
<volume>45</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>78-81</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<source><![CDATA[Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products]]></source>
<year>1965</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Umemura]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[A historical overview of Japan´s pharmaceutical industry.The japanese pharmaceutical industry: its evolution and current challenges.]]></source>
<year>2011</year>
<page-range>16-7</page-range><publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[Routledge]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="book">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[Principles for the cinical evaluation of drugs. World Health Organization technical report series.]]></source>
<year>1968</year>
<numero>403</numero>
<issue>403</issue>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="book">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[Principles for the cinical evaluation of drugs. World Health Organization technical report series.]]></source>
<year>1975</year>
<numero>563</numero>
<issue>563</issue>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="">
<collab>International Council for Harmonisation (ICH)</collab>
<source><![CDATA[The need to harmonise]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<collab>European Medicines Evaluation Agency (EMA)</collab>
<article-title xml:lang=""><![CDATA[European Medicines Evaluation Agency and the new licensing arrangements]]></article-title>
<source><![CDATA[Drug Ther Bull.]]></source>
<year>1994</year>
<volume>32</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>89-90</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sauer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hankin]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rules governing pharmaceuticals in the European Community.]]></article-title>
<source><![CDATA[J Clin Pharmacol.]]></source>
<year>1987</year>
<volume>27</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>639-46</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vijayananthan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nawawi]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The importance of Good Clinical Practice guidelines and its role in clinical trials.]]></article-title>
<source><![CDATA[Biomed Imaging Interv J.]]></source>
<year>2008</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="book">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[Fifth International Conference of Drug Regulatory Authorities]]></source>
<year></year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<collab>International Council for Harmonisation (ICH)</collab>
<article-title xml:lang=""><![CDATA[International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use.]]></article-title>
<source><![CDATA[Int Dig Health Legis.]]></source>
<year>1997</year>
<volume>48</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>231-4</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cartwright]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The common technical document - a global format for registration files]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Cartwright]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Matthews]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[International Pharmaceutical Product Registration]]></source>
<year>2010</year>
<edition>2</edition>
<page-range>1-2</page-range><publisher-loc><![CDATA[Boca Raton, Fl ]]></publisher-loc>
<publisher-name><![CDATA[CRC Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[PF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Third international conference on harmonization of technical requirements for registration of pharmaceuticals for human use--a toxicologist&#8217;s perspective.]]></article-title>
<source><![CDATA[Toxicol Pathol]]></source>
<year>1996</year>
<volume>24</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>519-28</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Horton]]></surname>
<given-names><![CDATA[LR.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Harmonization, regulation, and trade: where do we go from here?]]></article-title>
<source><![CDATA[PDA J Pharm Sci Technol.]]></source>
<year>1996</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>61-5</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ohno]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ICH guidelines-implementation of the 3Rs (refinement, reduction, and replacement): incorporating best scientific practices into the regulatory process.]]></article-title>
<source><![CDATA[ILAR J.]]></source>
<year>2002</year>
<numero>43^sS95-8</numero>
<issue>43^sS95-8</issue>
<supplement>S95-8</supplement>
</nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calam]]></surname>
<given-names><![CDATA[DH.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Design and international harmonization of pharmacopoeial standards]]></article-title>
<source><![CDATA[J Pharm Biomed Anal.]]></source>
<year>1995</year>
<volume>14</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="book">
<collab>International Council for Harmonisation (ICH)</collab>
<source><![CDATA[ICH Harmonised Tripartite Guideline. Guideline for Good Cinical Practice E6(R1)]]></source>
<year>1996</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[ICH]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="book">
<collab>International Council for Harmonisation (ICH)</collab>
<source><![CDATA[ICH Harmonised Tripartite Guideline. Guideline for Good Cinical Practice E6(R2).]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[ICH]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="book">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[Guidelines for Good Clinical Practice (GCP) for trials on pharmaceutical products. WHO. Technical report series, No. 850, Annex 3 - WHO Expert committee on selection and use of essential medicines, Sixth Report, 1993]]></source>
<year>1995</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Idanpaan-Heikkila]]></surname>
<given-names><![CDATA[JE.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[WHO guidelines for good clinical practice (GCP) for trials on pharmaceutical products: responsibilities of the investigator.]]></article-title>
<source><![CDATA[Ann Med.]]></source>
<year>1994</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>89-94</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="book">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[Handbook for good clinical research practice (GCP): guidance for implementation]]></source>
<year>2005</year>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osorio]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What everybody should know about good clinical practices.]]></article-title>
<source><![CDATA[Biomedica]]></source>
<year>2015</year>
<volume>35</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>274-84</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="">
<collab>Pan American Health Organization (PAHO-WHO)</collab>
<source><![CDATA[Conferencia Panamericana sobe Armonización de la Reglamentación Farmacéutica]]></source>
<year>1998</year>
</nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="">
<collab>Pan American Health Organization (PAHO-WHO)</collab>
<source><![CDATA[IV Conferencia Panamericana sobe Armonización de la Reglamentación Farmacéutica]]></source>
<year>2005</year>
</nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="">
<collab>Organización Panamericana de la Salud (OPS-WHO)</collab>
<source><![CDATA[Buenas Prácticas Clínicas: Documento de las Américas]]></source>
<year>2005</year>
</nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="book">
<collab>World Health Organization (WHO)</collab>
<source><![CDATA[Operational guidelines for ethics committees that review biomedical research]]></source>
<year>2000</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[World Health Organization]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vidal]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comités de ética de la investigación]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Tealdi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Saada]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Diccionario Latinoamericano de Bioética]]></source>
<year>2008</year>
<page-range>107-15</page-range><publisher-loc><![CDATA[Bogotá D.C. ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Nacional de Colombia UNIBIBLOS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lozano-León]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Informe Final AsesoríaConvenio 245 de 2004 suscrito entre la Pontificia Universidad Javeriana y el Ministerio de la Protección Social para el &#8220;Diseño, elaboración y validación de las normas de buena práctica clínica para centros que conducen investigación de medicamentos en sujetos humanos&#8221;.]]></source>
<year>2005</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[PUJ]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="">
<collab>Invima</collab>
<source><![CDATA[Investigación Clínica. Instituciones certificadas en buenas prácticas clínicas 2019]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="">
<collab>Invima</collab>
<source><![CDATA[Investigación Clínica. Comités de ética vinculados a instituciones certificadas en buenas prácticas clínicas 2019]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[GA.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical research monitoring: scenarios and challenges]]></article-title>
<source><![CDATA[Rev Soc Bras Med Trop.]]></source>
<year>2013</year>
<volume>46</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-6</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="">
<collab>República de Colombia. Ministerio de Protección Social</collab>
<source><![CDATA[Resolución 2378 de 2008. Por la cual se adoptan las Buenas Prácticas Clínicas para las instituciones que conducen investigación con medicamentos en seres humanos]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="">
<collab>Avanzar</collab>
<source><![CDATA[Cursos Básicos BPC 2019]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="">
<collab>Fundación Universitaria de Ciencias de la Salud (FUCS)</collab>
<source><![CDATA[Curso de Buenas Prácticas Clínicas (BPC) 2019]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="">
<collab>Universidad CES</collab>
<source><![CDATA[Curso buenas prácticas clínicas 2016]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="">
<collab>Infonetica</collab>
<source><![CDATA[Online GCP 2019]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="">
<collab>National Institutes of Health (NIH)</collab>
<source><![CDATA[The Good Clinical Practice (GCP) course 2019]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Duque-Ortiz]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Diálogos Nacionales sobre Ética de la Investigación. Memorias 2013-2014]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Colombia ]]></publisher-loc>
<publisher-name><![CDATA[Departamento Administrativo de Ciencia, Tecnología e Innovación]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
